← Back to patent-cliff list
CAS 1247119-36-3
(S)-ethyl 2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanoate oxalate
Codes: COBI-037
Application context (from source-drug indications)
HIV infectionCobicistatNon-small cell lung cancerCobicistatAcquired immunodeficiency syndromeCobicistat
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Cobicistat | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-(2-isopropylthiazol-4-yl)-N-methylmethanamine→(2R,5R)-1,6-diphenylhexane-2,5-diamine→4-nitrophenyl (thiazol-5-ylmethyl) carbonate→(S)-3-aminodihydrofuran-2(3H)-one hydrobromide→(S)-1-((2-isopropylthiazol-4-yl)methyl)-1-methyl-3-(2-oxotetrahydrofuran-3-yl)urea→morpholine→(S)-2-benzylaziridine→dimethylsulfamoyl chloride→(S)-2-benzyl-N,N-dimethylaziridine-1-sulfonamide→COBI-030→(2S,5S,E)-1,6-diphenylhex-3-ene-2,5-diamine→(2R,5R)-1,6-diphenylhexane-2,5-diamine dihydrochloride→thiazol-5-ylmethyl ((2R,5R)-5-amino-1,6-diphenylhexan-2-yl)carbamate hydrochloride→potassium (S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanoate→(S)-2-amino-4-(methylthio)butanoic acid→(S)-ethyl 4-iodo-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanoate→(S)-ethyl 2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanoate oxalate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.